Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
WBA logo

Walgreens Boots Alliance Inc (WBA)WBA

Upturn stock ratingUpturn stock rating
Walgreens Boots Alliance Inc
$8.81
Delayed price
Profit since last BUY-14.92%
SELL
upturn advisory
SELL since 5 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/14/2024: WBA (1-star) is a SELL. SELL since 5 days. Profits (-14.92%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: SELL
Historic Profit: -18.36%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 20
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/14/2024
Type: Stock
Today’s Advisory: SELL
Historic Profit: -18.36%
Avg. Invested days: 20
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/14/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.17B USD
Price to earnings Ratio -
1Y Target Price 10.81
Dividends yield (FY) 12.06%
Basic EPS (TTM) -10.01
Volume (30-day avg) 23264511
Beta 0.67
52 Weeks Range 7.98 - 25.00
Updated Date 11/20/2024
Company Size Mid-Cap Stock
Market Capitalization 7.17B USD
Price to earnings Ratio -
1Y Target Price 10.81
Dividends yield (FY) 12.06%
Basic EPS (TTM) -10.01
Volume (30-day avg) 23264511
Beta 0.67
52 Weeks Range 7.98 - 25.00
Updated Date 11/20/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -5.85%
Operating Margin (TTM) 2.35%

Management Effectiveness

Return on Assets (TTM) 0.59%
Return on Equity (TTM) -75.97%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE 5.05
Enterprise Value 36910676007
Price to Sales(TTM) 0.05
Enterprise Value to Revenue 0.25
Enterprise Value to EBITDA -22.57
Shares Outstanding 864617024
Shares Floating 714320734
Percent Insiders 17.66
Percent Institutions 61.74
Trailing PE -
Forward PE 5.05
Enterprise Value 36910676007
Price to Sales(TTM) 0.05
Enterprise Value to Revenue 0.25
Enterprise Value to EBITDA -22.57
Shares Outstanding 864617024
Shares Floating 714320734
Percent Insiders 17.66
Percent Institutions 61.74

Analyst Ratings

Rating 2.89
Target Price 26.11
Buy 2
Strong Buy 1
Hold 12
Sell 2
Strong Sell 2
Rating 2.89
Target Price 26.11
Buy 2
Strong Buy 1
Hold 12
Sell 2
Strong Sell 2

AI Summarization

Walgreens Boots Alliance Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background:

Walgreens Boots Alliance Inc. (WBA) was formed in 2014 through the merger of Walgreens, a leading pharmacy chain in the United States, and Alliance Boots, a European pharmacy-led health and beauty retailer. The company boasts a rich history dating back to the 19th century, with the founding of Walgreens in Chicago in 1901 and Alliance Boots in Nottingham, England, in 1849. Today, WBA operates over 21,000 stores in 25 countries, employing more than 450,000 people.

Core Business Areas:

WBA focuses on three primary business segments:

  • Retail Pharmacy USA: This segment operates drugstores under the Walgreens, Duane Reade, and Boots brands in the United States, offering prescription and over-the-counter medications, health and beauty products, and photo services.
  • Retail Pharmacy International: This segment operates pharmacies and drugstores in over 20 countries outside the United States, including Boots in the UK, Ahumada in Chile, and Benavides in Mexico.
  • Pharmaceutical Wholesale: This segment distributes pharmaceutical products to pharmacies, hospitals, and other healthcare providers in over 20 countries.

Leadership and Corporate Structure:

  • CEO: Rosalind Brewer (since 2021)
  • Executive Chairman: Stefano Pessina (since 2014)
  • Board of Directors: Comprised of 12 members with diverse experience in business, finance, and healthcare.

Top Products and Market Share:

  • Prescription Medications: WBA is the second-largest pharmacy chain in the US based on prescriptions filled, holding an estimated market share of 13.3% as of 2022.
  • Over-the-Counter Medications: The company offers a wide range of OTC medications, both national brands and private label products.
  • Health and Beauty Products: WBA is a leading retailer of health and beauty products, offering cosmetics, skincare, hair care, and other personal care items.
  • Photo Services: WBA provides photo printing, custom photo gifts, and other photo-related services.

Market Share Analysis:

  • US Market: WBA holds the second-largest market share in the US pharmacy market, behind CVS Health (CVS).
  • Global Market: WBA is a leading global pharmacy retailer, with a significant presence in Europe, Latin America, and Asia.

Total Addressable Market (TAM):

The global pharmaceutical market is estimated to be worth over $1.5 trillion in 2023, with the US market accounting for approximately 40% of the total. The health and beauty market is also substantial, valued at over $500 billion globally.

Financial Performance:

  • Revenue: WBA generated $132.5 billion in revenue in fiscal year 2023, representing a 3.2% year-over-year increase.
  • Net Income: The company reported a net income of $4.3 billion in fiscal year 2023, a 9.4% decrease compared to the previous year.
  • Profit Margin: WBA's profit margin stood at 3.2% in fiscal year 2023.
  • Earnings per Share (EPS): Diluted EPS for fiscal year 2023 was $4.35, down 10.4% from the previous year.

Cash Flow and Balance Sheet:

WBA has a strong cash flow position, generating $6.4 billion in operating cash flow in fiscal year 2023. The company also maintains a solid balance sheet with total assets of $104.7 billion and total liabilities of $70.6 billion.

Continued in next response due to length limitations.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Walgreens Boots Alliance Inc

Exchange NASDAQ Headquaters Deerfield, IL, United States
IPO Launch date 1985-07-01 CEO & Director Mr. Timothy C. Wentworth
Sector Healthcare Website https://www.walgreensbootsalliance.com
Industry Pharmaceutical Retailers Full time employees 193000
Headquaters Deerfield, IL, United States
CEO & Director Mr. Timothy C. Wentworth
Website https://www.walgreensbootsalliance.com
Website https://www.walgreensbootsalliance.com
Full time employees 193000

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, Germany, the United Kingdom, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​